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 37 
Abstract 38 
Innate immune activation is essential to mount an effective antiviral response and to 39 
prime adaptive immunity. Although a crucial role of CD169
+
 cells during vesicular stomatitis 40 
virus (VSV) infections is increasingly recognized, factors regulating CD169
+
 cells during 41 
viral infections remain unclear. Here we show that tumor necrosis factor is produced by 42 
CD11b
+
 Ly6C
+
Ly6G
+
 cells following infection with VSV. The absence of TNF or TNF 43 
receptor 1 (TNFR1) resulted in reduced numbers of CD169
+
 cells and in reduced IFN-I 44 
production during VSV infection, with a severe disease outcome. Specifically, TNF triggered 45 
RelA translocation into the nucleus of CD169
+
 cells; this translocation was inhibited when 46 
paracaspase MALT-1 was absent. Consequently, MALT1 deficiency resulted in reduced 47 
VSV replication, defective innate immune activation, and severe disease development. These 48 
findings indicate that TNF mediates the maintenance of CD169
+
 cells and innate and 49 
adaptive immune activation during VSV infection.  50 
Importance 51 
Over the last decade, strategically placed CD169
+
 metallophilic macrophages in the marginal 52 
zone of the murine spleen and LN have been shown to play a very important role in host 53 
defense against viral pathogens. CD169
+
 macrophages are shown to activate innate and 54 
adaptive immunity via “enforced virus replication” a controlled amplification of virus 55 
particles.  However, factors regulating the CD169
+ 
macrophages remain to be studied. In this 56 
paper, we show that after Vesicular stomatitis virus infection, phagocytes produce tumor 57 
necrosis factor (TNF) which signals via TNFR1 and promote “enforced virus replication” in 58 
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CD169
+
 macrophages. Consequently, lack of TNF or TNFR1 resulted in defective immune 59 
activation and VSV clearance.  60 
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Introduction  61 
Innate immune activation is crucial for inducing antiviral immunity through cytokine 62 
production and adaptive immune priming (1). Splenic marginal zone macrophages and 63 
metallophilic marginal zone macrophages play an important role in eliminating blood borne 64 
bacterial, parasites and viral pathogens (2, 3). Metallophilic macrophages were originally 65 
described when rat splenic marginal zone macrophages were stained with iron and silver 66 
impregnation (4). These metallophilic macrophages express the lectin like hemagglutinin 67 
CD169, which was identified using a monoclonal antibody: MOMA-1 (5-7).  CD169
+
 68 
macrophages are increasingly recognized to play a pivotal role in host defense (8). CD169
+
 69 
macrophages (referred to as CD169
+ 
cells), specifically allow early viral replication  to 70 
promote innate immune recognition and antigen presentation (9). The absence of CD169
+
 71 
cells results in reduced type I interferon (IFN-I) production, reduced B-cell activation, and 72 
severe disease development during viral infection (10, 11). B cell–derived lymphotoxin alpha 73 
(Ltα) and lymphotoxin beta (LTβ) drive the maintenance of CD169+ cells in spleen and 74 
lymph node tissue (10, 12, 13). Consequently, B cell–deficient mice exhibit fewer CD169+ 75 
cells and limited immune activation, including the production of IFN-I (13, 14). However, 76 
factors promoting survival and the presence of CD169
+
 cells after viral infection have not yet 77 
been sufficiently studied.  78 
IFN-I triggers strong inhibitory effects on viral replication and is crucial for 79 
preventing severe infections with the vesicular stomatitis virus (VSV) model system (1, 15). 80 
This system can be used as a laboratory system for immune recognition during viral 81 
infection, as a vaccine vector system, as a tool for viral transduction, and as an oncolytic 82 
virus (16, 17). Clearance of VSV depends heavily on IFN-I and the presence of neutralizing 83 
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antibodies (15, 18). VSV has been used as a murine model of viral infections to study the 84 
innate immune response, virus replication in secondary lymphoid organs and the central 85 
nervous system (CNS) (19-21). Pathology during VSV infection is seen particularly during 86 
infection of the central nervous system (CNS); this pathology includes paralysis and death 87 
after infection with VSV (22). Accordingly, mice deficient in IFN-α/β receptor (IFNAR) 88 
signaling exhibit paralysis and the presence of VSV in the CNS (15). Consistently, IFN-I can 89 
inhibit VSV replication in neurons, and defects in IFN-stimulated genes in the CNS tissue 90 
trigger pathology during VSV infection (23, 24). During infection with low doses of VSV, 91 
replication of VSV in CD169
+
 cells in the spleen and lymph node tissue is important for 92 
inducing protective immunity and preventing CNS infection (9, 10). The VSV backbone is 93 
also used during vaccination to induce protective immunity against viruses such as the Ebola 94 
virus (25).   95 
The role of tumor necrosis factor (TNF) in marginal zone development and marginal 96 
zone function is controversial. Although reports show that marginal zone development is 97 
impaired and fewer marginal zone macrophages are present in TNF-deficient and p55-TNFR 98 
(tumor necrosis factor receptor 1 [TNFR1])-deficient mice (26), other reports suggest that 99 
TNF triggers marginal zone macrophage depletion after infection (27, 28). It has also been 100 
shown that TNFR1 deficient mice are less susceptible to West Nile virus infection as a result 101 
of uncompromised blood brain barrier (29). However, these findings are contradicting other 102 
studies utilizing Herpes simplex virus-1 as infection model where it is shown that TNFR1 103 
deficient mice are more susceptible to virus infection (30, 31).  It is clear that TNF-deficient 104 
mice exhibit CD169
+
 cells in the spleen, whereas this cell population is absent in Ltα-/- mice 105 
(26, 27). Furthermore, the production of neutralizing antibodies and the proliferation of 106 
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antiviral T cells can be induced in TNF-deficient animals (28, 32).  These findings suggest 107 
that TNF, which is crucial for overcoming bacterial infections (33-36) plays a minor role in 108 
antiviral immunity.  109 
In this study, we found that absence of TNF reduced the number of CD169
+
 cells, 110 
inhibited IFN-I production, and consequently led to a severe disease outcome during 111 
infection with VSV. These effects were mainly transmitted by TNFR1 and were dependent 112 
on canonical nuclear factor (NF)-B.  113 
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Results 114 
TNF production by CD11b
+
Ly6C
+
Ly6G
+ 
cells following VSV infection.  115 
TNF can be detected during an infection with VSV (32, 37). Consistently, we found 116 
that TNF expression levels were higher in the spleen after infection with VSV when 117 
compared to uninfected controls (Fig. 1A). Backgating of intracellular TNF
 
producing cells 118 
showed that TNF-producing cells are a heterogeneous CD11b
+
 CD19
-
 population (Fig. 119 
1B+C). Therefore, we hypothesized that TNF was likely not expressed by B or T cells during 120 
infection. Accordingly, we observed TNF mRNA expression levels in Cd8
-/-
, B cell–deficient 121 
Jh
-/-
, and Rag1
-/-
 mice comparable to WT mice (Fig. 1D). TNF producing cells could be 122 
predominantly characterized as CD11b
+
CD11c
-
Ly6C
+
Ly6G
+
MHCII
-
 (Fig. 1E). Consistent 123 
with reports that neutrophils (38, 39) and CD11b
+
Ly6C
+
Ly6G
+ 
 cells (40)
 
 are important 124 
during early defense against bacterial and viral infections via production of proinflammatory 125 
cytokines such as IL1b, IL6, TNF and IFN-I, we found a significant increase of 126 
TNF
+
CD11b
+
Ly6C
+
Ly6G
+ 
cells (Fig. 1F). Treatment with clodronate liposomes can deplete 127 
phagocytic cells in mice (Fig. 1G)(41, 42). Accordingly, clodronate depletion reduced TNF 128 
expression after VSV infection suggesting a role of these phagocytic cells in the production 129 
of TNF (Fig. 1H). However, when we employed diphtheria toxin- receptor (DTR) induced 130 
specific cell depletion of CD169
+
 cells and CD11c
+
 cells; we did not observe reduction in 131 
TNF production (Fig.1H). Taken together, these findings indicate that TNF production 132 
following intravenous VSV infection is triggered by CD11b
+
CD11c
-
Ly6C
+
Ly6G
+ 
133 
phagocytes.  134 
 135 
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TNF triggers the maintenance of CD169
+
 cells during viral infection to protect animals 136 
against the development of severe disease  137 
To determine whether TNF affects the outcome after VSV infection, we infected 138 
wild-type (WT) and TNF-deficient mice. TNF-deficient mice developed severe VSV 139 
infection in comparison to WT mice (Fig. 2A). Neutralizing antibody titer was achieved later 140 
in TNF-deficient mice than in WT mice after infection with low doses of VSV (Fig. 2B). 141 
Since IFN-I is critical to overcome an infection with VSV (15), we measured IFN alpha and 142 
IFN beta in the serum of infected animals. IFN alpha production was impaired in TNF-143 
deficient mice when compared to control animals (Fig. 2C). However, IFN beta was 144 
undetectable in the serum of infected animals when infected with 10
5 
PFU VSV (Fig. 2C). 145 
Previous findings show that CD169
+
 cells contribute to innate immune activation not only by 146 
allowing viral replication but also by producing IFN-I in mice (10, 43). When we depleted 147 
CD169
+
 cells expressing diphtheria toxin receptor (CD169-DTR) by administering diphtheria 148 
toxin (DT) (44), we observed reduced IFN-I concentrations in the serum of infected animals 149 
(Fig. 2D). To exclude the possibility of defective innate Toll-like receptor (TLR) activation, 150 
we administered the TLR3 agonist poly I:C. We found that the IFN-I production was intact in 151 
both WT and TNF-deficient mice (Fig. 2E). Hence, we speculated that TNF promoted the 152 
function of CD169
+
 cells and thus contributed to IFN-I production following VSV infection. 153 
Shortly after infection with VSV, the number of CD169
+
 cells in spleen tissue decreased in 154 
TNF-deficient mice when compared to spleen tissue harvested from WT animals (Fig. 2F-H). 155 
To understand the reduced production of IFN-I in absence of TNF, we monitored the virus 156 
replication in spleen tissue of WT and Tnfa
-/- 
mice. The expression of VSV glycoprotein 157 
(VSV-G) was detected in lower quantities in spleen tissue harvested from TNF-deficient 158 
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animals compared to WT mice after VSV infection (Fig. 2I+J). Consistently, early VSV titers 159 
after infection were lower in Tnfa
-/-
 mice than in control mice, a condition that negatively 160 
affects antiviral immune activation (Fig. 2K). Injection of ultraviolet light (UV)-inactivated 161 
virus could increase TNF mRNA expression in WT mice (Fig. 2L). However, decrease of 162 
CD169
+ 
cells was dependent on live virus, because UV-inactivated virus did not affect 163 
CD169
+
 cells in spleen tissue of Tnfa
-/-
 mice (Fig. 2M). These findings indicate that TNF is 164 
necessary to sustain virus replication in early hours of infection but is dispensable for sterile 165 
innate immune activation. Notably, CD169
–/–
 mice exhibited VSV-G expression in spleen 166 
tissue, a finding indicating that downregulation of the protein CD169 would not cause 167 
absence of virus replication (Fig. 2N). Taken together, these findings indicate that the 168 
absence of TNF results in defective antiviral innate immune activation after infection with 169 
VSV.  170 
 171 
 CD169
+
 cell maintenance via TNFR1 results in productive VSV replication and 172 
immune activation 173 
To further characterize the role of TNF during viral infection, we infected TNFR1- 174 
and TNFR2-deficient mice with VSV. In line with findings from TNF-deficient animals, the 175 
absence of TNFR1 but not that of TNFR2 resulted in a decrease in the number of CD169
+
 176 
cells in spleen tissue (Fig. 3A + B). Furthermore, VSV-G production was lower in Tnfrsf1a
-/-
 177 
animals than in WT or Tnfrsf1b
-/-
 mice (Fig. 3A). Consistently, VSV titers were reduced in 178 
spleen tissue shortly after infection in Tnfrsf1a
-/-
 animals, in sharp contrast to the findings in 179 
WT and Tnfrsf1b
-/-
 mice (Fig. 3C). Interestingly, IFN-I production was defective in Tnfrsf1a
-
180 
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/-
 mice but was also lower in Tnfrsf1b
-/-
 animals than in WT control mice (Fig. 3D). IFN-I is 181 
necessary for the expression of anti-virally active IFN-stimulated genes (ISGs) (1). 182 
Consistently, we found reduced expression of ISGs in the CNS of Tnfrsf1a
–/–
 mice after 183 
infection with VSV (Fig. 3E). Defective ISG expression was not found to the same extent in 184 
Tnfrsf1b
–/–
 CNS tissue (Fig. 3F). VSV can drive neuropathological symptoms by infecting 185 
the CNS (22). When we measured viral titers in the spinal cord and brain tissue of mice 186 
exhibiting hind leg paralysis, we found infectious VSV in tissue from TNFR1-deficient mice 187 
(Figure 3G).  Consequently, Tnfrsf1a
-/-
 mice developed clinical signs of CNS infection, 188 
unlike WT and Tnfrsf1b
-/-
 mice (Fig. 3H). Taken together, these findings suggest that TNFR1 189 
drives antiviral defense by promoting CD169
+
 cell survival.  190 
 191 
TNFR1 triggers the survival of CD169
+
 cells  192 
Next, we opted to determine which factors drive the maintenance of CD169
+
 cells and 193 
enforced viral replication after viral infection. B cell–mediated Ltβ production is important 194 
for splenic CD169
+
 cells. Hence, we wondered whether the defects in absence of TNF were 195 
triggered by B cells. Notably, we did not observe any major changes of B-cell subsets in 196 
TNF, TNFR1 or TNFR2-deficient mice (Fig. 4A). Consistently, we did not see differential 197 
expression of Ltα, Ltβ, or Ltβ receptor (LtbR) in TNFR1-deficient mice (Fig. 4B). 198 
Additionally, we found no major differences in B-cell subsets between WT and Tnfrsf1a
-/-
 199 
mice after infection (Fig. 4C). Furthermore, we reconstituted lethally irradiated C57BL/6 200 
mice with mixed bone marrow from Rag1
–/–
 and Tnfrsf1a
–/–
 and Rag1
–/– 
and WT donors at a 201 
ratio of 1:1. Mice reconstituted with Rag1
–/–
: Tnfrsf1a
–/–
 bone marrow exhibited no 202 
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significant reduction in IFN-α in the serum when compared to mice reconstituted with Rag1–203 
/–
:
 
WT bone marrow (Fig. 4D). Furthermore, there was no difference between these mice in 204 
neutralizing antibody production (Fig. 4E). To elucidate if TNFR1 deficiency specifically on 205 
CD169
+ 
cells have a role in virus replication, we reconstituted lethally irradiated C57BL/6 206 
mice with mixed bone marrow from CD169-DTR
+
 and Tnfrsf1a
–/–
 donors as well as CD169-207 
DTR
+
 and WT donors at a ratio of 1:1. We observed that the production of IFN-α was lower 208 
in the mice reconstituted with CD169-DTR
+
 + Tnfrsf1a
–/–
  bone marrow compared to control 209 
mice reconstituted with CD169-DTR
+
 + WT after infection with VSV and DT treatment (Fig. 210 
4F). Furthermore, we found slightly delayed presence of VSV neutralizing antibody titers in 211 
CD169-DTR
+
:Tnfrsf1a
–/–
 recipients when compared to corresponding CD169-DTR
+
:WT 212 
recipients (Fig. 4G). CD169
+
 cells can be depleted in CD11c-DTR mice, because CD169
+
 213 
cells exhibit intermediate expression of CD11c (10, 45). Consistently, lethally irradiated mice 214 
reconstituted with mixed bone marrow from CD11c-DTR
+ 
and Tnfrsf1a
–/–
 mice exhibited 215 
reduced concentrations of IFN-α after VSV infection when compared to CD11c-DTR+ :WT 216 
recipients (Fig. 4H). These findings suggest that TNFR1 triggers cell-intrinsic effects on 217 
CD169
+
 cells.  218 
We speculated that TNF delivers an important survival signal for CD169
+
 cells. To 219 
determine if TNF is involved in protection against VSV induced apoptosis, we measured 220 
caspase 3 activity on whole spleen tissue lysates. After VSV infection caspase 3 activity was 221 
significantly higher in Tnfa
-/-
 mice compared to control animals (Fig. 5A). VSV is known to 222 
induce apoptosis and inactivates Mcl-1 and Bcl-Xl (46).  To elucidate if TNF plays a role in 223 
promoting expression of anti-apoptotic genes, we measured mRNA expression of Bcl2, Bcl-224 
Xl and xIAP in spleen tissue of mice after VSV infection (Fig. 5B). After VSV infection, 225 
 o
n
 N
ovem
ber 20, 2017 by Brought to you by the University of Dundee Library & Learning Centre
http://jvi.asm.org/
D
ow
nloaded from
 
12 
 
Bcl2 and Bcl-Xl expression was significantly reduced in Tnfa
-/- 
mice compared to WT mice 226 
(Fig. 5B). To enumerate the mechanism which reduces CD169
+ 
cells in TNF deficient mice 227 
after infection we made use of terminal deoxynucleotidyl transferase dUTP nick end 228 
labelling (TUNEL) assay. The number as well as the mean fluorescence intensity of TUNEL-229 
positive CD169
+
 cells was higher in spleen tissue from TNF deficient mice than in tissue 230 
from corresponding WT control mice (Fig. 5C+D). The proportion of CD169
+
 cells that 231 
stained positive for 7-aminoactinomycin D (7-AAD) was higher in TNFR1-deficient mice 232 
than in WT control mice 8h after infection (Fig. 5E). Next, we wondered if we can rescue the 233 
CD169
+ 
cells by injecting the pan-caspase inhibitor Z-Val-Ala-Asp-fluoromethylketone 234 
(zVAD-FMK). Z-VAD treatment restored the presence of CD169
+
 cells in TNF-deficient 235 
animals, a finding indicating that CD169
+
 cells depend on TNF-mediated survival (Fig. 236 
5F+G). Although treatment of TNF-deficient mice with Z-VAD rescued CD169
+
 cells, it 237 
failed to rescue the IFN-I response suggesting the role of TNF signaling is not only essential 238 
to prevent apoptosis, but also for IFN-I production (Fig. 5H). In summary, these findings 239 
indicate that TNF delivers a survival signal that is important for the maintenance of CD169
+
 240 
cells in the spleen after viral infection and IFN-I production.  241 
 242 
The NF-κB regulator MALT1 promotes canonical NF-κB expression, VSV replication 243 
in CD169
+
 cells, and immune activation during viral infection 244 
TNF can induce NF-κB activation via TNFR1 and can promote the expression of 245 
genes driving survival and of proinflammatory cytokines (47). Furthermore, TNF is known to 246 
promote IFN-I production (48). Consistently, RelA expression was increased in the marginal 247 
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zone of spleen tissue after VSV infection (Fig. 6A). We quantified cytoplasmic and nuclear 248 
expression of RelA in CD169
+ 
cells. Nuclear presence of RelA in CD169
+
 cells was higher in 249 
VSV-infected mice than in naïve controls (Fig. 6B). We wondered whether nuclear RelA 250 
expression was dependent on TNF. As expected, compared with WT control mice, VSV-251 
infected mice exhibited reduced expression of RelA in the nuclear compartment of CD169
+
 252 
cells in absence of TNF (Fig. 6C). Notably, the presence of RelA was reduced in TNFR1 253 
deficient mice, but we observed no difference in RelA expression between TNFR2-deficient 254 
mice and corresponding control mice (Fig. 6D+E). It has been reported that one of the major 255 
regulator of RelA signaling is RelB which acts through sequestration of RelA in the 256 
cytoplasm and competitive binding of DNA (49). It is also reported that  the paracaspase 257 
MALT1 can promote canonical NF-κB signaling by cleaving RelB (50, 51). Hence, we 258 
stained spleen sections of Malt1
+/–
 and Malt1
–/–
  mice for RelB. Ablation of MALT1 resulted 259 
in increased levels of RelB in CD169
+
 cells in the marginal zone of the spleen (Fig. 7A+B). 260 
In turn, nuclear RelA levels were lower in CD169
+
 cells in Malt1
–/–
 spleen tissue than in 261 
control tissue (Fig. 7C). Consistently, mouse embryonic fibroblasts (MEFs) derived from 262 
Malt1
–/– 
mice showed reduced translocation of p65 into the nucleus after stimulation with 263 
TNF but higher expression of RelB in the nucleus (Fig. 7D+E).  These findings indicate that 264 
MALT1 destabilizes RelB in marginal zone macrophages to promote canonical NF-κB 265 
signaling. The presence of CD169
+
 cells in spleen tissue was not affected by Malt1 before or 266 
after infection with VSV (Fig. 8A). However, the expression of VSV-G was lower in Malt1
-/-
 267 
mice than in control mice (Fig. 8B+C). Consistently, the number of infectious VSV particles 268 
were lower in spleen tissue harvested from Malt1
-/-
 mice than in spleen tissue from control 269 
mice (Fig. 8D). Hence, IFN-I serum concentrations after VSV infection were lower in 270 
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MALT1 deficient mice than in control mice (Fig. 8E). A previous report suggests that 271 
MALT1 is not required for RIG-I activation (52). Consistently, when we injected polyI:C 272 
into Malt1
+/ -
 and Malt1
-/-
  mice, we found similar serum IFN-I levels in both groups (Fig. 273 
8F). Hence we concluded that defective IFN-I production during VSV infection was caused 274 
by reduced VSV replication early during infection. Consequently, MALT1 deficient mice 275 
succumbed to the infection in sharp contrast to control animals (Fig. 8G).  276 
Taken together, these findings indicate that absence of MALT1 results in reduced 277 
canonical NF-κB signaling in response to VSV infection. Malt1-deficient mice exhibit 278 
reduced VSV replication and immune activation.  279 
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Discussion 280 
In this study, we found that TNF plays a crucial role in the maintenance of CD169
+
 281 
cells early after infection with VSV. Consequently, TNF, TNFR1, and MALT1 deficient 282 
animals exhibited reduced immune activation, limited IFN-I production, which consequently 283 
led to a sever VSV infection.   284 
The role of TNF during viral infection is controversial and not sufficiently 285 
understood. Although reports describe activating polymorphisms in TNF, which are 286 
associated with the establishment of a chronic viral infection (53), other reports state that the 287 
same mutations are protective against chronic hepatitis B virus infection (HBV) (54). In 288 
vitro, TNF can propagate the viral replication of HCV (55) although HCV increases the 289 
incidence of TNF-induced apoptosis (56). On the other hand, TNF strongly inhibits influenza 290 
virus replication in porcine lung epithelial cells (57). Consistently, the attenuation of TNF 291 
signaling in a murine T cell–independent model of HBV infection results in viral persistence 292 
(58). In turn, the application of Smac mimetics enhances TNF signaling and is associated 293 
with increased clearance of HBV in this model system (59). During infection with VSV, the 294 
production of neutralizing antibodies is not defective in the absence of TNFR1 (32). 295 
Moreover, TNF can induce T-cell dysfunction and, therefore, promote chronic viral infection 296 
(60). Our findings that TNF is crucial for the maintenance of CD169
+
 cells in spleen tissue 297 
may be important for infections with lower doses of virus, because allowing viral replication 298 
in CD169
+
 cells is particularly important for protective adaptive immunity (9, 13). This may 299 
be crucial for the maintenance of CD169
+
 cells in spleen tissue during vaccination with 300 
attenuated virus strains or VSV vector–based vaccines (25).  These findings may not only be 301 
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specific for splenic CD169
+ 
cells, since intranasal infection with recombinant TNF 302 
overexpressing  Rabies virus (RV), reduced RV load and mortality (61). 303 
Viral replication in CD169
+
 cells, which is promoted by TNF, contributes to 304 
improved antigen presentation. CD169
+
 cells in the marginal zone are in close contact with 305 
pathogens and are ideally situated to induce an immune response (62). Furthermore, CD169
+
 306 
cells have been shown not only to present antigens to B cells in the lymph nodes but also to 307 
prime T cells (11, 63). Moreover, CD169
+
 cells are important for virus-mediated IFN-I 308 
production which prevents severe CNS infection in mice (64). Our findings show that TNF 309 
promotes maintenance of CD169
+
 cells and IFN-I production following VSV infection. 310 
Furthermore, our findings show that the translocation of RelA to the nuclei of CD169
+
 cells 311 
after VSV infection is dependent on TNF. It has been postulated that canonical NF-κB can 312 
contribute to the production of IFN-α (65, 66). However, RelA-deficient and p50-deficient 313 
MEFs can produce IFN-α after viral infection, whereas only early IFN-I transcription is 314 
reduced (67, 68). Furthermore, RelA-deficient plasmacytoid dendritic cells (pDCs) exhibited 315 
reduced IFN production after exposure to Sendai virus (69). Our findings indicate that 316 
canonical NF-κB activation can also promote early viral replication and consequently 317 
contribute to the production of IFN-I. Consistently, non-canonical NF-κB, which can inhibit 318 
canonical NF-κB signaling, is a potent inhibitor of IFN-I production (70). Hence, the 319 
paracaspase MALT1, which can cleave RelB and consequently promote canonical NF-κB 320 
signaling (50, 51) is necessary for the sufficient propagation of VSV replication and IFN-I 321 
production.  322 
Taken together, we have found that TNF-TNFR1 signaling is crucial for protecting 323 
CD169
+
 cells and their function in innate immune activation during VSV infection.   324 
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Materials and Methods: 325 
Mice, viruses, virus titration: Tnfa
-/-
, Tnfrsf1b
-/-
, Cd8
-/-
 and Rag1
-/-
 mice were purchased 326 
from Jackson Laboratories (United States). Tnfrsf1a
-/-
 mice have been previously described 327 
(34). Malt1
-/-
, CD169
-/-
, CD169-DTR, and CD11c-DTR mice have also been previously 328 
described (71-74). All mice were maintained on a C57BL/6 genetic background. VSV 329 
Indiana strain (VSV-IND, strain Mudd-Summers) was originally obtained from Prof. D. 330 
Kolakofsky (University of Geneva, Switzerland). VSV was propagated and titrated as 331 
previously described (13). Mice were infected with VSV via tail vein injection. In survival 332 
experiments, mice exhibiting symptoms of hind leg paralysis were considered severe, taken 333 
out of the experiment, and counted as dead. Blood was collected at the indicated time points 334 
after infection. VSV neutralizing antibody titers were measured by plaque reduction 335 
neutralization test (PRNT) as previously described (9, 13). Briefly, serum samples were 336 
diluted 1:40 and incubated at 56ºC for 30 min. To evaluate IgG, serum was pretreated with 337 
0.1M β-mercaptoethanol. Serial 2 fold dilutions were performed for 12 steps and incubated 338 
with 5000 PFU of VSV. Virus and serum mixture was incubated on a Vero cell monolayer. 339 
Plates were stained with crystal violet after 24h. To inhibit caspase activity in vivo, we 340 
administered three doses (2 µg/g each) of zVAD-FMK (Abcam, Cambridge, UK) (75, 76). 341 
For chimera experiments, mice were lethally irradiated with 10.2 Gy. After 24 h, mixed bone 342 
marrow from WT or Tnfrsf1a
–/–
 and CD169-DTR, CD11c-DTR, and Rag1
-/-
 mice was 343 
transplanted into the irradiated mice as indicated. All mice were maintained under specific 344 
pathogen–free conditions at the authorization of the Landesamt für Natur, Umwelt und 345 
Verbraucherschutz of North Rhine-Westphalia (LANUV NRW) in accordance with the 346 
German laws for animal protection.  347 
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Depletion of cells: To deplete macrophages, 200ul clodronate liposomes was injected 348 
intravenously, 24h later mice were infected with VSV. Clodronate was provided by Nico van 349 
Rooijen and used as previously described (41, 42)(Vrije University Medical Center, 350 
Netherlands). CD169
+
 and CD11c
+ 
expressing cells in CD169-DTR and CD11c-DTR mice 351 
were depleted by injecting 2 doses of 100ng diphtheria toxin (DT) (Sigma) 1 day before and 352 
at the day of infection.  353 
 354 
Histology and ELISA: Histological analysis of snap-frozen tissue was performed as 355 
previously described (9). Briefly, Snap-frozen tissue sections were cut in 7μm thickness, air 356 
dried and fixed with acetone for 10min. Sections were blocked with 2% fetal calf serum in 357 
PBS for 1h. Sections were stained with anti-CD169 (final conc. 4 μg/ml) (Acris, Germany; 358 
clone: MOMA-1), anti-VSV-G (final conc. 1 μg/ml) (produced in-house, clone: Vi10), anti-359 
RelA (final conc. 1μg/ml) (Santa Cruz Biotechnology, USA), anti-F4/80 (final conc. 2μg/ml) 360 
(eBioscience, clone BM8) and anti-RelB (final conc. 1μg/ml) (Cell Signaling,  USA; 361 
polyclonal) for 1h. Then Sections were washed with PBS containing 0.05% Tween 20 362 
(Sigma).  Secondary antibodies, PE streptavidin (final conc. 1μg/ml) (eBioscience), anti-363 
Rabbit FITC (final conc. 1μg/ml) (Thermofisher), anti-Goat FITC (final conc. 1μg/ml) (Santa 364 
Cruz Biotechnology, USA) were incubated for 1h. Then sections were washed with PBS 365 
containing 0.05% Tween 20 (Sigma) and mounted using fluorescence mounting medium 366 
(Dako).  Caspase 3 activity assay was performed with a fluorescence assay according to the 367 
manufacturer’s instructions (Cell Signaling). TUNEL staining was performed on formalin-368 
fixed spleen sections according to the manufacturer’s instructions (Thermo scientific, USA). 369 
Images were obtained with a LSM510 confocal microscope and Axio Observer Z1 370 
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fluorescence microscope (Zeiss, Germany). Analysis of the fluorescence images was 371 
performed with ImageJ software. IFN-α and IFN-β (PBL Biosciences, New Jersey, USA) 372 
concentrations were determined using enzyme-linked immunosorbent assay (ELISA) 373 
according to the manufacturers’ instructions.  374 
RT-PCR analyses: RNA purification was performed according to manufacturer’s 375 
instructions (Qiagen RNeasy Kit or Trizol). Gene expression of Bcl2, Bcl-xl, Xiap, Lta, Ltb, 376 
Ifit1, Ifit2, Ifit3, Irf7, Isg15, Oasl1 and Tnfa, was performed using FAM/VIC probes (Applied 377 
Biosystems) and iTAQ™ One step PCR kit (Bio rad). For analysis, the expression levels of 378 
all target genes were normalized to β-actin/GAPDH expression (∆Ct). Gene expression 379 
values were then calculated based on the ∆∆Ct method, using naive WT mice as a control to 380 
which all other samples were compared. Relative quantities (RQ) were determined using the 381 
equation: RQ=2^-∆∆Ct. 382 
Immunoblotting: Malt1
+/-
 and Malt1
-/-
 mouse embryonic fibroblasts (MEFs) were obtained 383 
from Jürgen Ruland (Technische Universität München, Germany). Malt1
+/-
 and Malt1
-/-
 384 
MEFs were stimulated with 100 ng/ml murine-soluble TNF (mTNF; R&D Systems). 385 
Cytoplasmic and nuclear extracts were prepared according to manufacturer’s instructions 386 
(Active Motif, Belgium). Immunoblots were probed with primary anti-p65 (Santa Cruz 387 
Biotechnology), anti-RelB (Cell Signaling), and anti-p100/p52 (Cell Signaling). 388 
Flow cytometry: For intracellular cytokine staining, single-cell suspended splenocytes were 389 
incubated with Brefeldin A (eBioscience), followed by an additional 5 h of incubation at 390 
37°C. After surface staining with anti-CD3, anti-CD8, anti-CD11b, anti-CD11c, anti-CD19, 391 
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anti-CD115, anti-F4/80, anti-Ly6C, anti-Ly6G anti-MHC-II, and anti-NK1.1 antibodies (all 392 
from eBioscience), cells were fixed with 2% formalin, permeabilized with 0.1% saponin, and 393 
stained with anti-TNF antibodies (eBioscience) for 30 min at 4°C. B-cell subsets were 394 
detected in single-cell suspensions of splenocytes with anti-CD5, anti-CD19, anti-CD21, 395 
anti-CD23, and anti–immunoglobulin M (IgM) antibodies (all from eBioscience). BD 396 
Calibrite™ (BD Biosciences, USA) beads were added to the samples before acquisition by BD 397 
LSRFortessa™. 398 
 399 
Statistical analyses:  Data are represented as +SEM or ±SEM. Statistically significant 400 
differences between two groups were determined with Student’s t-test. Statistically 401 
significant differences between several groups were determined by one-way analysis of 402 
variance (ANOVA) with additional Bonferroni or Dunnett post hoc test. Statistically 403 
significant differences between groups in experiments involving more than one time-point 404 
were determined with two-way ANOVA (repeated measurements).  405 
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Figure Legends 674 
Fig. 1:  Vesicular stomatitis virus infection leads to infiltration of TNF producing 675 
phagocytes.  676 
 (A to F) WT mice were infected with 2 × 10
8
 PFU vesicular stomatitis virus (VSV). (A) 677 
Tumor necrosis factor (TNF)-α mRNA expression levels in WT spleen tissue were 678 
determined at the indicated time points after infection (n=4-10). (B)  Surface molecule 679 
expression of CD11b, CD11c, CD8, and CD19 on TNF
+
 cells is shown 4h after infection 680 
(purple gate, whole spleen; pink gate, TNF
+ 
cells) (one representative result of n=5 is shown). 681 
(C) Splenocytes from WT mice were stained for intracellular TNF production. TNF
+
CD11b
+
 682 
cells were determined (as % of total CD11b
+
 cells; n=5). (D) TNF-α mRNA expression was 683 
determined in the spleen of WT, Jh
-/-
, Rag
-/-
, and CD8
-/-
 mice 4 h after infection (n=5-6). (E) 684 
Surface molecule expression of TNF producing cells is shown 4h after infection. CD3
-
CD8
-
685 
CD19
-
NK1.1
-
 cells were further characterized for expression of CD11b, CD11c, Ly6C, 686 
Ly6G, F4/80, MHC II, and CD115 on TNF
+ 
cells (n=6). (F) CD3
-
CD8
-
CD19
-
NK1.1
-
687 
CD11b
+
Ly6C
+
Ly6G
+
TNF
+
 cells were quantified in spleen tissue 4h after infection (n=6). 688 
(G) Mice were injected with PBS-liposomes or clodronate- liposomes. Spleen tissue was 689 
harvested after 24h. Sections from snap frozen spleen tissue were stained with anti-F4/80 690 
antibodies (n=3). (H) TNF-α mRNA expression was determined in the spleen of WT, 691 
clodronate-treated WT, Ifnar
-/-
, DT-treated CD169-DTR, and CD11c-DTR mice 4 h after 692 
infection (n=6).  693 
 694 
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Fig. 2: Tumor necrosis factor is required for early innate immune activation via 695 
maintenance of CD169
+
 cells during viral infection. 696 
(A to D) Mice were infected with 10
5
 PFU VSV. (A) Survival of Wild-type (WT) and tumor 697 
necrosis factor-α null (Tnfa-/-) mice was monitored for 20 days after infection (n=9-12). (B) 698 
Titers of neutralizing total immunoglobulin (Ig; left) and IgG (right) were determined in WT 699 
and Tnfa
-/-
 mice at indicated time points after infection (n=7).  (C) Interferon (IFN)-α and β 700 
concentrations were determined in the sera of WT and Tnfa
-/-
 mice 24 h after infection (n=6-701 
9). (D) IFN-α levels were determined in sera from WT and CD169-DTR mice 24 h after 702 
infection (n=6). (E) IFN-α and β concentration was determined in the sera of WT and Tnfa-/- 703 
mice injected with 200µg of polyinosinic:polycytidylic acid (polyI:C) at indicated time 704 
points (n=3). (F)  WT and Tnfa
-/-
 mice were infected with 2 × 10
8
 plaque-forming units 705 
(PFU) of VSV. Snap-frozen spleen sections were stained with anti-CD169 antibodies (clone: 706 
MOMA-1) at indicated time points (one representative result of n=6 mice is shown; scale bar 707 
= 100 µm). (G) MFI of CD169 was quantified across spleen section from naïve and VSV 708 
infected WT and Tnfa
-/-
 mice using ImageJ (1-3 images per spleen from 3-4 mice were 709 
analyzed). (H) MFI from Tnfa
-/-
 mice was normalized to WT MFI (I) Snap-frozen spleen 710 
sections from WT and Tnfa
-/-
 mice were stained for VSV glycoprotein (VSV-G) expression 711 
(clone: Vi10) after infection with 2 × 10
8
 PFU VSV at indicated time points (one 712 
representative result of n=6 mice is shown; scale bar = 100µm). (J) MFI of VSV-G 713 
expression was quantified across spleen section from naïve and VSV infected WT and Tnfa
-/-
 714 
mice using ImageJ (1-3 images per spleen from 3-4 mice were analyzed) (K) WT and Tnfa
-/-
 715 
mice were infected with 10
5
 PFU VSV. Viral titers were measured in the spleen of WT and 716 
Tnfa
-/-
 mice 8 h after infection with VSV (n=6). (L) Tnfa mRNA expression was determined 717 
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in spleen tissue of WT mice before and 4h after injection with UV-inactivated VSV (n=4). 718 
(M) Spleen tissue sections were stained with anti-CD169 antibodies in WT and Tnfa
-/-
 mice 719 
8h after infection with 2×10
8
 PFU of ultraviolet (UV)-inactivated VSV (one representative 720 
result of n=3 is shown). (N) Sections from snap-frozen spleen tissue harvested from WT and 721 
CD169
-/-
 mice were stained for CD169 and VSV-G 7h after infection with 2×10
8
 PFU VSV 722 
(n=3; scale bar = 100 µm).  723 
 724 
Fig. 3: VSV replication is sustained via TNFR1 on CD169
+ 
cells. 725 
(A) Spleen tissue sections from wild-type (WT), Tnfrsf1a
-/-
 (tumor necrosis factor receptor 1 726 
[TNFR1]), and Tnfrsf1b
-/-
 (TNFR2) mice were stained with anti-CD169 and VSV-G 727 
antibodies 8 h after infection with 2 × 10
8
 PFU of VSV (One representative result of n=6 728 
mice is shown; scale bar = 100µm). (B) MFI of CD169 was quantified across spleen sections 729 
from WT, Tnfrsf1a
-/-
, and Tnfrsf1b
-/- 
infected mice, using ImageJ (1-3 images per spleen from 730 
3-4 mice were analyzed). (C-G) WT, Tnfrsf1a
-/-
, and Tnfrsf1b
-/-
 mice were infected with 10
5
 731 
PFU VSV. (C) Viral titers were measured in spleen tissue 8h after infection in WT, Tnfrsf1a
-
732 
/-
,
 
and Tnfrsf1b
-/-
 mice (n=6-9). (D) IFN-α concentration was determined in the sera of WT, 733 
Tnfrsf1a
-/-
, and Tnfrsf1b
-/-
 mice 24 h after infection with VSV (n=6-9). (E) WT and Tnfrsf1a
-
734 
/-
 mice were infected with 10
5
 PFU VSV. RNA expression levels of indicated genes were 735 
determined in brain and spinal cord 24 h after infection (n=4-7, highest relative expression 736 
values brain/spinal cord: Eif2ak2, 13.72/7.98; Ifit2, 5.41/6.13; Ifit3, 35.99/34.15; Irf7, 737 
68.80/54.55; Isg15, 42.54/51.23; Oasl1, 70.43/84.94). (F) WT and Tnfrsf1b
-/-
 mice were 738 
infected with 10
5
 PFU VSV. RNA expression levels of indicated genes were determined in 739 
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brain and spinal cord 24h after infection (n=3-4, highest relative expression values 740 
brain/spinal cord: Eif2ak, 29.84/18.21; Ifit2, 7.99/10.24; Ifit3, 41.05/51.25; Irf7, 741 
166.79/88.58; Isg15, 29.78/52.99; Oasl1, 75.60/114.39). (G) Viral titers were measured in 742 
brain and spinal cord tissue of WT and Tnfrsf1a
-/-
 mice, once Tnfrsf1a
-/-
 mice exhibited hind 743 
limb paralysis (n=3). (H) Survival of WT, Tnfrsf1a-/-, and Tnfrsf1b-/- mice was monitored 744 
over time after infection with VSV (n=15-24).  745 
 746 
Fig. 4: TNFR1 on CD169
+
 cells is essential for early IFN-I response. 747 
(A) Follicular B cells (CD19
+
CD23
+
) (FB), marginal zone B cells (CD19
+
CD21
+ 
CD23
-
) 748 
(MZB), and regulatory B cells (CD19
+
CD21
+ 
CD5
+
IgM
+
) (RB) were analyzed in naïve WT, 749 
Tnfa
-/-
, Tnfrsf1a
-/-
, and Tnfrsf1b
-/-
 deficient mice (n=6). (B) Lymphotoxin α (LTα), LTβ, and 750 
lymphotoxin β receptor (LtβR) gene expression was determined in spleen tissue from WT 751 
and Tnfrsf1a
-/-
 mice by reverse-transcription polymerase chain reaction (RT-PCR) (n=3). (C) 752 
Splenic B-cell populations FB, MZB, and RB were analyzed after infection with 2×10
8
 PFU 753 
of VSV in WT and Tnfrsf1a
-/-
 mice at indicated time points (n=5). (D) IFN-α concentration 754 
was determined 24 h after infection with 10
5
 PFU VSV in the sera of lethally irradiated mice 755 
reconstituted with either WT:Rag
-/-
 or Tnfrsf1a
-/-
:Rag
-/-
 bone marrow at a ratio of 1:1 (n=4). 756 
(E) Neutralizing total immunoglobulin (Ig; left) and IgG (right) antibody titers were 757 
determined in the sera of WT:Rag
-/-
 or Tnfrsf1a
-/-
:Rag
-/- 
reconstituted animals (n=4). (F-H) 758 
Lethally irradiated WT mice were reconstituted with bone marrow (BM) from WT or 759 
Tnfrsf1a
-/-
 mice mixed with BM from (F) CD169-DTR and (H) CD11c-DTR at a 1:1 ratio. 760 
After 40 days, mice were infected with 10
5
 PFU of VSV. Before the infection mice were 761 
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treated with 2 doses of 100 ng DT via intra peritoneal injection (F) IFN-α concentration was 762 
determined 24h after infection in the sera of WT:CD169-DTR and Tnfrsf1a
-/-
:CD169-DTR 763 
reconstituted animals (n=4-5). (G) Neutralizing total immunoglobulin (Ig; left) and IgG 764 
(right) antibody titers were determined in the sera of WT:CD169-DTR and Tnfrsf1a
-/-
765 
:CD169-DTR reconstituted animals after infection with 10
5
 PFU VSV at indicated time 766 
points (n=4). (H) IFN-α concentration was determined 24 h after infection in the sera of 767 
WT:CD11c-DTR and Tnfrsf1a
-/-
:CD11c-DTR reconstituted mice (n=4-5).  768 
 769 
Fig. 5: Tumor necrosis factor mediates survival of CD169
+
 cells via TNFR1 770 
(A-E) Mice were infected with 2 × 10
8
 PFU VSV. (A) Caspase 3 activity was determined in 771 
spleen tissue harvested from WT and Tnfa
-/-
 mice 6h after infection with 2×10
8
 PFU VSV 772 
(n=4-7, RFU = relative fluorescence units). (B) Bcl2, Bclxl, Xiap RNA expression was 773 
determined in spleen tissue from WT and Tnfrsf1a
-/-
 mice 8h after infection (n=3). (C)   774 
Tissue sections from WT and Tnfa
-/-
 mice were stained with terminal deoxynucleotidyl 775 
transferase dUTP nick end labeling (TUNEL) 5 h after infection (one result representative of 776 
3 or 4 mice is shown; scale bar = 10 µm). (D)  Mean fluorescence intensity (MFI) of TUNEL 777 
was quantified across spleen sections from naïve and VSV infected WT and Tnfa
-/-
  mice 778 
using ImageJ (1-2 images per spleen from 3-4 mice were analyzed). (E) At indicated time 779 
points, the proportion of 7 aminoactinomycin D–positive (7AAD+) cells among 780 
CD11b
+
CD169
+
 cells were determined (n=5) in WT and Tnfrsf1a
-/- 
mice. (F) WT, Tnfa
-/-
 and 781 
Tnfrsf1a
-/- 
mice were treated with Z-Val-Ala-Asp-fluoromethylketone (zVAD-FMK) and 782 
infected with 2 × 10
8
 PFU VSV. Spleen tissue sections were stained with anti-CD169 783 
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antibodies 8 h after infection (one result representative of 3-4 mice is shown; scale bar = 100 784 
µm). (G) MFI of CD169 was quantified across spleen sections from naïve and VSV infected 785 
WT and Tnfa
-/-
 mice treated with Z-VAD using ImageJ (1-3 images per spleen from 3-4 mice 786 
were analyzed).  (H) IFN-α concentration was determined 24 h after infection in the sera of 787 
Z-VAD treated WT and Tnfa
-/-
 mice after infection with 10
5 
PFU of VSV (n=3).  788 
 789 
Fig. 6: VSV infection leads to TNFR1 dependent canonical NF-κB activation in splenic 790 
CD169
+
 cells.  791 
 (A-D) Sections of snap-frozen spleen tissue were harvested 4h after infection with 2 x 10
8
 792 
PFU VSV. (A) Sections were stained for RelA before and after infection (one representative 793 
result of n=3 is shown; scale bar = 100 µm; side panel shows a cropped image; scale bar = 5 794 
µm). (B) MFI of cytoplasmic and respective nuclear RelA was quantified in CD169
+
 cells 795 
from WT mice before and after VSV infection to evaluate nuclear translocation of RelA (n = 796 
48-63 are shown). (C to E) Spleen sections from WT and (C) Tnfa
-/-
, (D) Tnfrsf1a
-/- 
and (E) 797 
Tnfrsf1b
-/-
 mice were stained with anti-RelA antibodies 4h after infection with 2×10
8 
PFU 798 
VSV. MFI of RelA in the nucleus of CD169
+
 was determined with ImageJ software (n=35-799 
57). 800 
 801 
 Fig. 7: MALT1 regulates translocation of RelA into the nucleus after infection with 802 
vesicular stomatitis virus. 803 
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(A) Sections from snap-frozen spleen tissue harvested from naive Malt1
+/-
 and Malt1
-/-
 mice 804 
were stained with anti-RelB antibodies (one representative result of n=3 is shown; scale bar = 805 
10 µm). (B) MFI of cytoplasmic and nuclear RelB was quantified in CD169
+
 cells using 806 
ImageJ (n=39-42). (C) Sections of snap-frozen spleen tissue from Malt1
+/-
 and Malt1
-/-
 mice 807 
were stained with anti-RelA antibodies 4h after infection with 2 x 10
8
 PFU VSV. The MFI in 808 
the nucleus of CD169
+
 cells was quantified (n=29-41). (D+E) Malt1
+/-
 and Malt1
-/-
 mouse 809 
embryonic fibroblasts (MEFs) were stimulated with 100 ng/ml recombinant mouse tumor 810 
necrosis factor (rmTNF) at indicated time points. Cytosolic (CE) and nuclear extracts (NE) 811 
were harvested and probed for p65. Densitometry analysis of p65 and RelB was performed 812 
on the WB images from cytosolic and nuclear fractions at indicated time points. Proteins 813 
were normalized to GAPDH or histone (n=4). 
 
814 
Fig. 8: MALT1 promotes vesicular stomatitis virus replication in CD169
+
 cells and 815 
immune activation during viral infection. 816 
(A) Spleen sections from naïve Malt1
+/-
 and Malt1
-/-
 mice were stained with anti-CD169 (one 817 
representative result of n=3 is shown; scale bar = 100 µm). (B) Sections of snap-frozen 818 
spleen tissue from Malt1
+/-
 and Malt1
-/-
 mice were analyzed 8h after infection with 2 x 10
8
 819 
PFU VSV, stained with anti-CD169 and anti–vesicular stomatitis virus glycoprotein (VSV-820 
G) (one representative result of n=3 is shown; scale bar = 100 µm). (C) MFI of CD169 and 821 
VSV-G was quantified across spleen sections from VSV infected Malt1
+/-
 and Malt1
-/-
 mice 822 
using ImageJ (n=4). (D and E) Mice were infected with 10
5
 PFU VSV. (D) Viral titers were 823 
measured in spleen tissue of Malt1
+/-
 and Malt1
-/-
 mice 8h after infection (n=6). (E) IFN-α 824 
concentration was determined in the sera of Malt1
+/-
 and Malt1
-/-
 mice 24 h after infection 825 
(n=6). (F)  IFN-α concentration was determined in the sera of Malt1+/- and Malt1-/- mice 826 
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injected with 200µg polyinosinic:polycytidylic acid (poly I:C) at indicated time points (n=3-827 
4).  (G) Survival of Malt1
+/-
 and Malt1
-/-
 animals was monitored for 20 days after infection 828 
(n=13-14).  829 
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